Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd (NQ: TLSA )

0.8200 +0.0299 (+3.78%)
Streaming Delayed Price Updated: 10:59 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 544,738
Open 0.7505
Bid (Size) 0.8200 (4)
Ask (Size) 0.8425 (10)
Prev. Close 0.7901
Today's Range 0.7505 - 0.8799
52wk Range 0.4100 - 0.9650
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
+43.83%
+43.83%
1 Month
+81.02%
+81.02%
3 Month
+43.86%
+43.86%
6 Month
+28.33%
+28.33%
1 Year
-6.19%
-6.19%

More News

Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
7 Battered Blue-Chip Stocks to Bounce From Your Portfolio This Spring
Via InvestorPlace
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
3 EV Stocks to Buy on the Dip: March 2024
Via InvestorPlace
Topics Electric Vehicles
Exposures Electric Vehicles
3 EV Stocks to Buy for the Next Bull Run: March 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
7 Over-Hyped Stocks to Sell Before They Plunge
Via InvestorPlace
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Don't Get Caught In Equity Rally Hype: Lessons From 2023 To Remember In 2024
Via Benzinga
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.